scholarly journals Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

2016 ◽  
Vol 29 (10) ◽  
pp. 1118-1142 ◽  
Author(s):  
Ruifang Sun ◽  
L Jeffrey Medeiros ◽  
Ken H Young
Keyword(s):  
Precision Medicine ◽  
Predictive Biomarkers ◽  
Diagnosis And Treatment

Avenues to Precision Oncology

2020 ◽  
pp. 36-45
Author(s):  
Alexander Meisel
Keyword(s):  
Precision Medicine ◽  
Trial Design ◽  
Ad Hoc ◽  
Molecular Targets ◽  
Clinical Trial Design ◽  
Predictive Biomarkers ◽  
Precision Oncology ◽  
Companion Diagnostics ◽  
Bona Fide ◽  
The One

Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with ad hoc guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as bona fide targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design.

Precision Medicine, Data-Driven Diagnosis and Treatment

2017 ◽  
pp. 15-34
Author(s):  
Harry Glorikian ◽  
Malorye Allison Branca
Keyword(s):  
Precision Medicine ◽  
Data Driven ◽  
Diagnosis And Treatment

scholarly journals Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles

2021 ◽  
Vol 3 (Supplement_5) ◽  
pp. v35-v42
Author(s):  
Ariane Steindl ◽  
Priscilla K Brastianos ◽  
Matthias Preusser ◽  
Anna S Berghoff
Keyword(s):  
Brain Metastases ◽  
Precision Medicine ◽  
Tumor Tissue ◽  
Metastatic Cancer ◽  
Predictive Biomarkers ◽  
Current Evidence ◽  
Therapeutic Decision ◽  
Molecular Alteration ◽  
Mortality And Morbidity ◽  
Therapeutic Decision Making

Abstract Brain metastases (BM) present a common cause of mortality and morbidity in several metastatic cancer entities. New therapeutic developments during the last decades, including targeted and immune-related therapies, have shown considerable extra- and intracranial response rates in specific subgroups of BM patients. However, differences in the molecular alteration in the BM tumor tissue compared to extracranial tumors leads to heterogeneous therapeutic responses. Therefore, an accurate molecular analyzation of BM tissue, if possible, has become an essential part in therapeutic decision making in BM patients. The concordance of predictive molecular biomarkers between multiple sites including extracranial and intracranial tumor tissue have been analyzed for some but not all biomarkers routinely applied in modern precision medicine approaches. In the present review, we summarize the current evidence of predictive biomarkers for personalized therapy approaches in the treatment of parenchymal BM.

Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era

2020 ◽  
pp. 53-61 ◽  
Author(s):  
Jing Yan ◽  
Zhuan Liu ◽  
Shengfang Du ◽  
Jing Li ◽  
Li Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Precision Medicine ◽  
Diagnosis And Treatment

scholarly journals Leveraging Genomics for Head and Neck Cancer Treatment

2018 ◽  
Vol 97 (6) ◽  
pp. 603-613 ◽  
Author(s):  
J.D. Kemmer ◽  
D.E. Johnson ◽  
J.R. Grandis
Keyword(s):  
Head And Neck ◽  
Precision Medicine ◽  
Predictive Biomarkers ◽  
Molecular Targeting ◽  
Data Sets ◽  
Genetic Characteristics ◽  
Multiple Data ◽  
Genomic Landscape ◽  
Multiple Data Sets ◽  
Molecular Targeting Agents

The genomic landscape of head and neck squamous cell carcinoma (HNSCC) has been recently elucidated. Key epigenetic and genetic characteristics of this cancer have been reported and substantiated in multiple data sets, including those distinctive to the growing subset of human papilloma virus (HPV)–associated tumors. This increased understanding of the molecular underpinnings of HNSCC has not resulted in new approaches to treatment. Three Food and Drug Administration–approved molecular targeting agents are currently available to treat recurrent/metastatic disease, but these have exhibited efficacy only in subsets of HNSCC patients, and thus surgery, chemotherapy, and/or radiation remain as standard approaches. The lack of predictive biomarkers to any therapy represents an obstacle to achieving the promise of precision medicine. This review aims to familiarize the reader with current insights into the HNSCC genomic landscape, discuss the currently approved and promising molecular targeting agents under exploration in laboratories and clinics, and consider precision medicine approaches to HNSCC.

scholarly journals Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3743
Author(s):  
Tet Woo Lee ◽  
Amy Lai ◽  
Julia K. Harms ◽  
Dean C. Singleton ◽  
Benjamin D. Dickson ◽  
...  
Keyword(s):  
Head And Neck ◽  
Precision Medicine ◽  
Patient Survival ◽  
Predictive Biomarkers ◽  
Tumour Microenvironment ◽  
Response To Therapy ◽  
Preclinical Models ◽  
Therapeutic Success ◽  
Patient Derived Xenograft ◽  
Individualise Therapy

Patient survival from head and neck squamous cell carcinoma (HNSCC), the seventh most common cause of cancer, has not markedly improved in recent years despite the approval of targeted therapies and immunotherapy agents. Precision medicine approaches that seek to individualise therapy through the use of predictive biomarkers and stratification strategies offer opportunities to improve therapeutic success in HNSCC. To enable precision medicine of HNSCC, an understanding of the microenvironment that influences tumour growth and response to therapy is required alongside research tools that recapitulate the features of human tumours. In this review, we highlight the importance of the tumour microenvironment in HNSCC, with a focus on tumour hypoxia, and discuss the fidelity of patient-derived xenograft and organoids for modelling human HNSCC and response to therapy. We describe the benefits of patient-derived models over alternative preclinical models and their limitations in clinical relevance and how these impact their utility in precision medicine in HNSCC for the discovery of new therapeutic agents, as well as predictive biomarkers to identify patients’ most likely to respond to therapy.

scholarly journals Predictive biomarkers in precision medicine and drug development against lung cancer

2015 ◽  
Vol 34 (3) ◽  
Author(s):  
Bingliang Fang ◽  
Reza J Mehran ◽  
John V Heymach ◽  
Stephen G Swisher
Keyword(s):  
Lung Cancer ◽  
Drug Development ◽  
Precision Medicine ◽  
Predictive Biomarkers
Sign in / Sign up

Export Citation Format

Share Document